Medivation and Astellas Announce New Preclinical Study Results Showing MDV3100 Blocks Breast Cancer Cell Growth

Medivation, Inc. MDVN and Astellas Pharma Inc. today announced results from a preclinical study conducted by researchers at the University of Colorado Denver that provide evidence that MDV3100 inhibits proliferation of breast cancer cells. In different cell-based assays, MDV3100 was able to inhibit both androgen- and estrogen-mediated breast cancer cell proliferation. MDV3100 is a triple-acting, oral androgen receptor antagonist in clinical development to treat a broad spectrum of advanced prostate cancer patients.